A blockade with PD-1/PD-L1 antibodies (Abs) has thus become a standard-of-care therapeutic option for patients with lung cancer; however, less than 30% of patients respond to the treatment of immune checkpoint blockade therapy [15,16]. This evidence concerns the gene CD274 and lung cancer.